| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5096890 | ABBVIE | Pyrrolidine derivatives |
Mar, 2015
(9 years ago) | |
| US6106864 | ABBVIE | Pharmaceutical formulations containing darifenacin |
Aug, 2016
(7 years ago) | |
Enablex is owned by Abbvie.
Enablex contains Darifenacin Hydrobromide.
Enablex has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Enablex are:
- US5096890
- US6106864
Enablex was authorised for market use on 22 December, 2004.
Enablex is available in tablet, extended release;oral dosage forms.
Enablex can be used as treating a disease of altered motility or tone of smooth muscle by administering a muscarinic receptor antagonizing amount of darifenacin, treating urinary incontinence by administering an extended-release form of darifenacin.
The generics of Enablex are possible to be released after 21 August, 2016.
Drugs and Companies using DARIFENACIN HYDROBROMIDE ingredient
Market Authorisation Date: 22 December, 2004
Treatment: Treating a disease of altered motility or tone of smooth muscle by administering a muscarinic receptor antagonizing amount of darifenacin; Treating urinary incontinence by administering an extended-re...
Dosage: TABLET, EXTENDED RELEASE;ORAL
ENABLEX family patents
